These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

820 related articles for article (PubMed ID: 15197147)

  • 1. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice.
    Navab M; Anantharamaiah GM; Reddy ST; Hama S; Hough G; Grijalva VR; Wagner AC; Frank JS; Datta G; Garber D; Fogelman AM
    Circulation; 2004 Jun; 109(25):3215-20. PubMed ID: 15197147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein A-I mimetic peptides.
    Navab M; Anantharamaiah GM; Reddy ST; Hama S; Hough G; Grijalva VR; Yu N; Ansell BJ; Datta G; Garber DW; Fogelman AM
    Arterioscler Thromb Vasc Biol; 2005 Jul; 25(7):1325-31. PubMed ID: 15831812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice.
    Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Wagner AC; Hama S; Hough G; Bachini E; Garber DW; Mishra VK; Palgunachari MN; Fogelman AM
    Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1932-7. PubMed ID: 15961700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral synthetic phospholipid (DMPC) raises high-density lipoprotein cholesterol levels, improves high-density lipoprotein function, and markedly reduces atherosclerosis in apolipoprotein E-null mice.
    Navab M; Hama S; Hough G; Fogelman AM
    Circulation; 2003 Oct; 108(14):1735-9. PubMed ID: 14504179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective down-regulation by protein kinase C inhibitors of apolipoprotein-mediated cellular cholesterol efflux in macrophages.
    Li Q; Tsujita M; Yokoyama S
    Biochemistry; 1997 Oct; 36(40):12045-52. PubMed ID: 9315842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of HDL apolipoprotein E in cellular cholesterol efflux: studies in apo E knockout transgenic mice.
    Hayek T; Oiknine J; Brook JG; Aviram M
    Biochem Biophys Res Commun; 1994 Dec; 205(2):1072-8. PubMed ID: 7802634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis.
    Sherman CB; Peterson SJ; Frishman WH
    Cardiol Rev; 2010; 18(3):141-7. PubMed ID: 20395699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human apolipoprotein AI mimetic peptides for the treatment of atherosclerosis.
    Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Hough G; Wagner A; Nakamura K; Garber DW; Datta G; Segrest JP; Hama S; Fogelman AM
    Curr Opin Investig Drugs; 2003 Sep; 4(9):1100-4. PubMed ID: 14582455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis.
    Wolfrum C; Poy MN; Stoffel M
    Nat Med; 2005 Apr; 11(4):418-22. PubMed ID: 15793583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective inhibition of free apolipoprotein-mediated cellular lipid efflux by probucol.
    Tsujita M; Yokoyama S
    Biochemistry; 1996 Oct; 35(40):13011-20. PubMed ID: 8855936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase.
    Aviram M; Rosenblat M; Bisgaier CL; Newton RS; Primo-Parmo SL; La Du BN
    J Clin Invest; 1998 Apr; 101(8):1581-90. PubMed ID: 9541487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct effect of an acyl-CoA:cholesterol acyltransferase inhibitor, F-1394, on atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice.
    Chiwata T; Aragane K; Fujinami K; Kojima K; Ishibashi S; Yamada N; Kusunoki J
    Br J Pharmacol; 2001 Aug; 133(7):1005-12. PubMed ID: 11487509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High density lipoprotein deficiency with xanthomas. A defect in reverse cholesterol transport caused by a point mutation in the apolipoprotein A-I gene.
    Lackner KJ; Dieplinger H; Nowicka G; Schmitz G
    J Clin Invest; 1993 Nov; 92(5):2262-73. PubMed ID: 7693760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation.
    Choudhury RP; Rong JX; Trogan E; Elmalem VI; Dansky HM; Breslow JL; Witztum JL; Fallon JT; Fisher EA
    Arterioscler Thromb Vasc Biol; 2004 Oct; 24(10):1904-9. PubMed ID: 15319266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel potent apoA-I peptide mimetics that stimulate cholesterol efflux and pre-beta particle formation in vitro.
    Ingenito R; Burton C; Langella A; Chen X; Zytko K; Pessi A; Wang J; Bianchi E
    Bioorg Med Chem Lett; 2010 Jan; 20(1):236-9. PubMed ID: 19932961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice.
    Westerterp M; van der Hoogt CC; de Haan W; Offerman EH; Dallinga-Thie GM; Jukema JW; Havekes LM; Rensen PC
    Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2552-9. PubMed ID: 16946130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.
    Ribas V; Sánchez-Quesada JL; Antón R; Camacho M; Julve J; Escolà-Gil JC; Vila L; Ordóñez-Llanos J; Blanco-Vaca F
    Circ Res; 2004 Oct; 95(8):789-97. PubMed ID: 15388641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substitution of the carboxyl-terminal domain of apo AI with apo AII sequences restores the potential of HDL to reduce the progression of atherosclerosis in apo E knockout mice.
    Holvoet P; Danloy S; Deridder E; Lox M; Bernar H; Dhoest A; Collen D
    J Clin Invest; 1998 Jul; 102(2):379-85. PubMed ID: 9664079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ApoA-I mimetic peptides promote pre-β HDL formation in vivo causing remodeling of HDL and triglyceride accumulation at higher dose.
    Carballo-Jane E; Chen Z; O'Neill E; Wang J; Burton C; Chang CH; Chen X; Eveland S; Frantz-Wattley B; Gagen K; Hubbard B; Ichetovkin M; Luell S; Meurer R; Song X; Strack A; Langella A; Cianetti S; Rech F; Capitò E; Bufali S; Veneziano M; Verdirame M; Bonelli F; Monteagudo E; Pessi A; Ingenito R; Bianchi E
    Bioorg Med Chem; 2010 Dec; 18(24):8669-78. PubMed ID: 21115285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenovirus mediated expression of human paraoxonase 2 protects against the development of atherosclerosis in apolipoprotein E-deficient mice.
    Ng CJ; Hama SY; Bourquard N; Navab M; Reddy ST
    Mol Genet Metab; 2006 Dec; 89(4):368-73. PubMed ID: 16935014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.